Abivax SA
Abivax Rides Health‑Care Rotation: Strong Valuation Backed by Vaccine & Antiviral Pipeline
Abivax SA: How a French biotech’s anti‑viral pipeline is riding a health‑care rotation and what clinical milestones could spark its next growth surge.
3 minutes to read
Abivax SA Gains Momentum After Truist Securities Issues Strong Buy Rating
Abivax SA sees renewed investor confidence as Truist Securities issues a buy rating, backed by a strong pipeline of antiviral and therapeutic vaccines targeting high‑growth markets in Asia and Latin America.
3 minutes to read
Abivax SA Soars with Record Capital Raise and Stock Surge Following Promising Clinical Data
Abivax SA successfully raised $747.5 million in capital and saw its stock price surge 586% after announcing positive Phase-3 data for its Colitis Ulcerosa treatment candidate.
2 minutes to read
Abivax SA’s Stock Soars on Promising Trial Results and Strategic Capital Increase
Abivax SA’s stock surged by 48% after positive late-stage trial results for its ulcerative colitis treatment, obefazimod, and a significant capital increase.
2 minutes to read
Abivax SA Stock Skyrockets on Promising Ulcerative Colitis Trial Results for Obefazimod
Abivax SA’s stock price surged over 500% after the company announced positive results from its Phase 3 clinical trials for its ulcerative colitis drug, Obefazimod.
2 minutes to read
Abivax SA Navigates Financial Uncertainty with Innovative Pipeline and Strategic Partnerships
Abivax SA, a Paris-based biotech firm, navigates financial uncertainty while advancing its innovative pipeline of anti-viral therapies and vaccines.
2 minutes to read